Zealand Pharma released Phase 2 results for petrelintide, an amylin analog partnered with Roche, showing mean weight loss up to 10.7% at 42 weeks and a tolerability profile the partners described as 'placebo‑like.' The dataset underpins a large commercial collaboration and validates amylin biology as a viable obesity modality alongside GLP‑1s. Roche’s involvement signals strategic interest from big pharma in differentiated obesity therapeutics. The Phase 2 readout could accelerate larger trials or regulatory planning depending on confirmatory safety and durability data; Roche’s role in late‑stage development and commercialization increases the program’s runway and potential market reach.